Shares of NovoCure Limited (NASDAQ:NVCR – Get Free Report) have received a consensus rating of “Moderate Buy” from the nine research firms that are currently covering the firm, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month […]